Aptamer-Based C3 Binding Agents for Stable Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and inhibiting the biological function of human complement component 3 (C3) protein are limited by the instability and high production costs of antibodies, as well as the need for specific therapeutic agents that can prevent excessive complement activation associated with various diseases.
Innovation Solution
Development of aptamers with specific binding sequences that inhibit the activation of C3 protein, including compositions comprising these aptamers and methods for their use in therapeutic and diagnostic applications, which are more stable and cost-effective than traditional antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used to detect C3 protein, then binding specificity is achieved, but stability and shelf-life are compromised
Solution Approach 1:
The patent uses aptamers as a synthetic copy alternative to natural antibodies. Aptamers are artificially selected nucleic acid sequences that can bind to C3 protein with high specificity, replicating the binding function of antibodies while offering superior stability and ease of production
Solution Approach 2:
The patent changes the fundamental parameter of the binding agent from protein-based (antibodies) to nucleic acid-based (aptamers). This parameter change transforms the molecular structure and properties, resulting in improved stability, tolerance to temperature and pH variations, and reduced aggregation while maintaining binding specificity
2Reliability
If antibodies are used for C3 detection, then binding capability is achieved, but production cost increases
Solution Approach 1:
The patent replaces expensive antibody production with a synthetic aptamer selection process (SELEX). This copying approach uses inexpensive nucleic acid synthesis and selection methodologies to create binding agents with comparable or superior performance, dramatically reducing production costs
Solution Approach 2:
The patent employs aptamers that can be synthesized cheaply through automated nucleic acid synthesis. These synthetic binding agents eliminate the need for complex animal or cell-based antibody production facilities, reducing manufacturing infrastructure costs and enabling scalable production
3Reliability
If antibodies are used for C3 detection, then binding specificity is achieved, but storage requirements become complex
Solution Approach 1:
The patent changes the chemical composition parameter from protein to nucleic acid, fundamentally altering the stability profile. Aptamers tolerate a broader range of temperatures and pH conditions without denaturation or aggregation, eliminating the need for refrigerated storage and simplifying distribution and storage logistics
4Reliability
If antibodies are used for C3 detection, then binding function is achieved, but aggregation occurs
Solution Approach 1:
The patent creates a synthetic nucleic acid-based copy of the antibody binding function. Aptamers form stable monomeric structures that do not undergo the aggregation phenomena observed with protein-based antibodies, eliminating this harmful side effect while preserving specific binding capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively inhibit C3 protein activation, providing a stable and economical solution for both therapeutic and diagnostic purposes, particularly in conditions involving excessive complement activation.
Implementation Method 1
aptamers capable of binding to human complement component 3 (C3 or C3-Protein)
Data Source
AI summary
Described herein are aptamers capable of binding to human complement component 3 (C3) protein; compositions comprising a C3 binding aptamer with a C3-Protein; and methods of making and using the same.